(P-1632) Effectiveness of remdesivir in patients with underlying hepatic or renal comorbidity hospitalized for SARS-CoV-2 infection

Wednesday, October 22, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Co-Author(s)

PG

Patrick Godwin, MD

Department of Medicine, University of Illinois College of Medicine
Chicago, Illinois, United States
JH

John Jay Hawkshead, DrPH

Gilead Sciences, Inc.
Foster City, California, United States
VS

Valentina Shvachko, MS

Gilead Sciences, Inc.
Foster City, California, United States
Thomas F. Oppelt, PharmD, BCPS

Sr. Director, Medical Affairs
Gilead Sciences, Inc
Foster City, California, United States
CW

Chen-Yu Wang, PhD

Gilead Sciences, Inc.
Foster City, California, United States
EM

Essy Mozaffari, PharmD, MPH, MBA

Gilead Sciences, Inc.
Foster City, California, United States
AL

Amos Lichtman, MPH, MD

Gilead Sciences, Inc.
Foster City, California, United States